134612-01-4

Upstream product

• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 121-33-5 vanillin 
• 134611-99-7 4-(benzyloxy)-3-methoxy-α-(3-phenylpropyl)benzyl alcohol 
• 134612-00-3 4'-(benzyloxy)-3'-methoxy-4-phenylbutyrophenone 

Downstream Products

• 873296-39-0 acetic acid 2-methoxy-4-(4-phenyl-butyryl)-phenyl ester 
• 383383-09-3 1-(4-hydroxy-3-methoxy-2-nitro-phenyl)-4-phenyl-butan-1-one 
• 134612-02-5 4'-hydroxy-3'-methoxy-5'-nitro-4-phenylbutyrophenone 

Relevant academic research and scientific papers

Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase

A homologous series of novel nitro-catechol structures (7a-7e) were synthesized and tested as inhibitors of the enzyme catechol-O-methyltransferase (COMT). Increasing chain length was found to have significant impact on both brain penetration and duration

Catechol derivatives

Catechol derivatives of the formula STR1 wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.